Genericsmaker banking on novel delivery to raise funds

Arkansas' Ezra Innovations is hoping its proprietary extended-release delivery tech can help it close a $6.5 million funding round. Using a novel drug design licensed from the University of Arkansas, the company wants to apply its method to generics. It figures its technology will allow for fewer doses and improved patient compliance, MedCity News reports. While it's unknown what meds Ezra is targeting, there are a number of blockbusters with soon-to-expire patents--including Cymbalta and Singulair--and the company's platform could help it get a leg up in the coming generic onslaught. Ezra has nailed down $4.2 million from 33 investors since April 2011. More

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…